[Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization].

Q4 Medicine Arkhiv patologii Pub Date : 2023-01-01 DOI:10.17116/patol20238503140

G A Raskin, M S Mukhina, E D Kravtsova, I V Tsimafeyeu, S A Tyulandin, N P Belyak, M A Kleshchev, R V Orlova

{"title":"[Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization].","authors":"G A Raskin, M S Mukhina, E D Kravtsova, I V Tsimafeyeu, S A Tyulandin, N P Belyak, M A Kleshchev, R V Orlova","doi":"10.17116/patol20238503140","DOIUrl":null,"url":null,"abstract":"Background: Assessment of FGFR2 status in gastric cancer is an important task, without clarification of which it is impossible to identify a cohort of patients in whom the best response to treatment with anti-FGFR2 drugs could be obtained.Objective: To conduct a comparative analysis of the expression and amplification of the FGFR2 gene in gastric cancer in primary tumors and metastases in the lymph nodes.Material and methods: FGFR2 status was studied in 61 patients with stage III gastric adenocarcinoma using an immunohistochemical method (Abcam clone EPR24075-418, R&D clone 98706, Santa Cruz clone C-8, Abcam clone 1G3) and FISH.Results: The antibody Abcam clone EPR24075-418 was found satisfactory for the immunohistochemical study of FGFR2. FGFR2 expression was detected in 26 (43%) cases, amplification in 5 (8%) cases. Amplification of FGFR2 in 4 cases out of 5 was accompanied by the expression of 3+, in 1 case - 2+. Discordance between FGFR2 expression in primary tumor and lymph node metastases was revealed in 13 (21%) cases.Conclusion: Clone EPR24075-418 showed the best result in assessing the expression of FGFR2: the correlation with FISH results in reaction 3+ was 100%. Due to the high heterogeneity of FGFR2 expression, it is recommended to either examine the material of the primary tumor and metastasis, or evaluate a large volume of the primary tumor.","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arkhiv patologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/patol20238503140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Assessment of FGFR2 status in gastric cancer is an important task, without clarification of which it is impossible to identify a cohort of patients in whom the best response to treatment with anti-FGFR2 drugs could be obtained.

Objective: To conduct a comparative analysis of the expression and amplification of the FGFR2 gene in gastric cancer in primary tumors and metastases in the lymph nodes.

Material and methods: FGFR2 status was studied in 61 patients with stage III gastric adenocarcinoma using an immunohistochemical method (Abcam clone EPR24075-418, R&D clone 98706, Santa Cruz clone C-8, Abcam clone 1G3) and FISH.

Results: The antibody Abcam clone EPR24075-418 was found satisfactory for the immunohistochemical study of FGFR2. FGFR2 expression was detected in 26 (43%) cases, amplification in 5 (8%) cases. Amplification of FGFR2 in 4 cases out of 5 was accompanied by the expression of 3+, in 1 case - 2+. Discordance between FGFR2 expression in primary tumor and lymph node metastases was revealed in 13 (21%) cases.

Conclusion: Clone EPR24075-418 showed the best result in assessing the expression of FGFR2: the correlation with FISH results in reaction 3+ was 100%. Due to the high heterogeneity of FGFR2 expression, it is recommended to either examine the material of the primary tumor and metastasis, or evaluate a large volume of the primary tumor.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[应用免疫组织化学和荧光原位杂交技术研究胃癌中FGFR2的状态]。

背景:评估胃癌中FGFR2的状态是一项重要的任务，如果不澄清这一点，就不可能确定一组患者对抗FGFR2药物治疗的最佳反应。目的:比较分析胃癌原发肿瘤和淋巴结转移灶中FGFR2基因的表达和扩增情况。材料和方法:采用免疫组织化学方法(Abcam克隆EPR24075-418, R&D克隆98706,Santa Cruz克隆C-8, Abcam克隆1G3)和FISH研究61例III期胃腺癌患者的FGFR2状态。结果:抗体Abcam克隆EPR24075-418可用于FGFR2的免疫组化研究。26例(43%)患者检测到FGFR2表达，5例(8%)患者检测到FGFR2扩增。5例中有4例FGFR2扩增伴有3+表达，1例- 2+表达。在13例(21%)原发肿瘤和淋巴结转移中发现FGFR2表达不一致。结论:克隆EPR24075-418对FGFR2表达的评估效果最好，与反应3+中FISH结果的相关性为100%。由于FGFR2表达的高度异质性，建议检查原发肿瘤和转移的材料，或评估原发肿瘤的大容量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Arkhiv patologii Medicine-Pathology and Forensic Medicine

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： The journal deals with original investigations on pressing problems of general pathology and pathologic anatomy, newest research methods, major issues of the theory and practice as well as problems of experimental, comparative and geographic pathology. To inform readers latest achievements of Russian and foreign medicine the journal regularly publishes editorial and survey articles, reviews of the most interesting Russian and foreign books on pathologic anatomy, new data on modern methods of investigation (histochemistry, electron microscopy, autoradiography, etc.), about problems of teaching, articles on the history of pathological anatomy development both in Russia and abroad.